Plain-English translation of NCT07219420 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can help people with palmoplantar pustulosis—a condition that causes painful pustules on the palms of the hands and soles of the feet. About 320 people will join the trial, and some will receive the medication while others initially receive a placebo (inactive treatment) before switching to the active medication later. Researchers want to understand how well and how safely this treatment works.
Palmoplantar pustulosis is a stubborn skin condition that can be painful and difficult to treat with existing options. This trial exists to see if this medication offers a new, more effective treatment for people who haven't found relief with current therapies.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to either receive the medication right away or receive a placebo first. You'll have regular clinic visits to monitor your skin, discuss any side effects, and let researchers measure how your pustules are improving. Eventually, all participants will have the opportunity to receive the active medication during an extended treatment phase. The trial includes both an initial blinded phase and an open-label extension, so you'll be involved for several months.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States